Journal of Cardiac Failure
Volume 13, Issue 5 , Pages 365-371 , June 2007

Effects of β-Blocker Therapy on High Sensitivity C-Reactive Protein, Oxidative Stress, and Cardiac Function in Patients With Congestive Heart Failure

  • Yuji Nagatomo, MD

      Affiliations

    • From the Cardiology Division, Department of Medicine, Keio University School of Medicine, Tokyo
    • ,
  • Tsutomu Yoshikawa, MD

      Affiliations

    • From the Cardiology Division, Department of Medicine, Keio University School of Medicine, Tokyo
    • Corresponding Author InformationReprint requests: Tsutomu Yoshikawa, MD, Cardiology Division, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan 160-8582.
    • ,
  • Takashi Kohno, MD

      Affiliations

    • From the Cardiology Division, Department of Medicine, Keio University School of Medicine, Tokyo
    • ,
  • Akihiro Yoshizawa, MD

      Affiliations

    • From the Cardiology Division, Department of Medicine, Keio University School of Medicine, Tokyo
    • ,
  • Toshihisa Anzai, MD

      Affiliations

    • From the Cardiology Division, Department of Medicine, Keio University School of Medicine, Tokyo
    • ,
  • Tomomi Meguro, MD

      Affiliations

    • Tokyo Electric Power Corporation Hospital, Tokyo, Japan
    • ,
  • Toru Satoh, MD

      Affiliations

    • From the Cardiology Division, Department of Medicine, Keio University School of Medicine, Tokyo
    • ,
  • Satoshi Ogawa, MD

      Affiliations

    • From the Cardiology Division, Department of Medicine, Keio University School of Medicine, Tokyo

Received 27 June 2006 ,Revised 14 February 2007 ,Accepted 19 February 2007.

References 

  1. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998;31:391–398
  2. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102:3060–3067
  3. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J. 2004;147:931–938
  4. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112:1428–1434
  5. Murray DR, Prabhu SD, Chandrasekar B. Chronic β-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation. 2000;101:2338–2341
  6. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL. β-Adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation. 2000;101:2103–2109
  7. Gullestad L, Ueland T, Brunsvig A, Kjekshus J, Simonsen S, Froland SS, et al. Effect of metoprolol on cytokine levels in chronic heart failure-A substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). Am Heart J. 2001;141:418–421
  8. Ohtsuka T, Hamada M, Hiasa G, Sasaki O, Suzuki M, Hara Y, et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;37:412–417
  9. Ohtsuka T, Hamada M, Saeki H, Ogimoto A, Hiasa G, Hara Y, et al. Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 2002;89:996–999
  10. Mayer B, Holmer SR, Hengstenberg C, Lieb W, Pfeifer M, Schunkert H. Functional improvement in heart failure patients treated with beta blockers is associated with a decline of cytokine levels. Int J Cardiol. 2005;103:182–186
  11. Kohno T, Yoshikawa T, Yoshizawa A, Nakamura I, Anzai T, Satoh T, et al. Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure. Cardiovasc Drugs Ther. 2005;19:347–355
  12. Ledue TB, Weiner DL, Sipe J, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A, and mannose binding protein in human serum. Ann Clin Biochem. 1998;35:745–753
  13. Tateishi T, Yoshimine N, Kuzuya F. Serum lipid peroxide assayed by a new colorimetric method. Exp Gerontol. 1987;22:103–111
  14. Pye M, Rae AP, Cobbe SM. Study of serum C-reactive protein concentration in cardiac failure. Br Heart J. 1990;63:228–230
  15. Sato Y, Takatsu Y, Kataoka K, Yamada T, Taniguchi R, Sasayama S, et al. Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute heart decompensation. Clin Cardiol. 1999;22:811–813
  16. Kaneko K, Kanda T, Yamauchi Y, Hasegawa A, Iwasaki T, Arai M, et al. C-reactive protein in dilated cardiomyopathy. Cardiology. 1999;91:215–219
  17. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, et al. Predictors of congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol. 2000;35:1628–1637
  18. Lamblin N, Mouquet F, Hennache B, Dagom J, Susen S, Bauters C, et al. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J. 2005;26:2245–2250
  19. Takahashi T, Anzai T, Yoshikawa T, Maekawa Y, Asakura Y, Satoh T, et al. Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction—role of neurohormones and cytokines. Int J Cardiol. 2003;88:257–265
  20. Anzai T, Yoshikawa T, Takahashi T, Maekawa Y, Okabe T, Asakura Y, et al. Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction. Cardiology. 2003;99:47–53
  21. Joynt KE, Gattis WA, Hasselblad V, Fuzaylov SY, Serebruany VL, Gurbel PA, et al. Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. Am J Cardiol. 2004;93:783–785
  22. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94:2817–2825
  23. Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz-Varley C, Ocampo ON, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation. 1999;99:2645–2651
  24. Josephson RA, Silverman HS, Lakatta EG, Stern MD, Zweier JL. Study of the mechanisms of hydrogen peroxide and hydroxyl free radical-induced cellular injury and calcium overload in cardiac myocytes. J Biol Chem. 1991;266:2354–2361
  25. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res. 1999;85:357–363
  26. Dalton TP, Shertzer HG, Puga A. Regulation of gene expression by reactive oxygen. Ann Rev Pharmacol Toxicol. 1999;39:67–101
  27. Tsutamoto T, Wada A, Matsumoto T, Maeda K, Mabuchi N, Hayashi M, et al. Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;37:2086–2092
  28. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation. 2002;105:2867–2871
  29. Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, et al. Carvedilol, a new vasodilator and β-adrenoreceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92–98
  30. Dandona P, Karne R, Ghanim H, Hamouda W, Alijada A, Magsino CH. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation. 2000;101:122–124
  31. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007
  32. Poole-Wilson PA, Swedberg K, Cleland JG, DiLenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7–13
  33. Venugopal SK, Devaraj S, Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol. 2005;166:1265–1271
  34. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16:3553–3562

PII: S1071-9164(07)00050-4

doi: 10.1016/j.cardfail.2007.02.004

Journal of Cardiac Failure
Volume 13, Issue 5 , Pages 365-371 , June 2007

Article Tools

* Image Usage & Resolution